In this week’s news, UK CPI launches nanomeds project, execs tell IQVIA that UK is less attractive due to Brexit, researchers develop microcrystal detection method and more…
CPI goes big on nanoformulations
The UK Centre for Process Innovation (CPI) has launched a nanomedicine project designed to foster collaboration between researchers, companies and academics working in the field.
The project will focus on the development and production of nanoformulated drugs with the support of the University of Manchester, the University of Strathclyde, AstraZeneca, Pfizer, Croda, Malvern PANalytical, and Precision Nanosystems according to an EPM report.
Nanomedicine and specifically nanofomulation is attracting a lot of drug industry attention. The advanced engineering techniques needed to tailor particles at the nanoscale have the potential to improve the efficacy of existing medicines and reduce side-effects.
A CPI spokeswoman told us, “The aim of the project is to establish and validate an open access capability for nanomedicines manufacture at CPI, which integrates the latest technology for production, purification and real-time analysis of nanomedicines. The infrastructure will be designed to support the pharma and biotech community to design robust and scalable processes for nanomedicine manufacture which will eventually be used to deliver supplies for clinical trials.
She added that, “Drug companies can participate by becoming members of the consortium. This could involve providing input, expertise and feedback into the design and utility of the capability. There is also an opportunity for prototype products to be evaluated as part of technical studies. These work packages will be designed to demonstrate that the capability is appropriate for its intended future use.”
UK less attractive due to Brexit say execs surveyed by IQVIA
Uncertainty surrounding Brexit has impacted how pharmaceutical executives see the UK as a place to do business according to a survey by IQVIA.
IQVIA market development director Angela McFarlane shared the results with SCRIP at Bio-Europe Spring conference, explaining 44% of execs surveyed said Brexit had made the UK a less attractive place to launch medicines.
Some respondents also suggested they would consider a 2-3 year delay when launching a drug in the UK.
McFarlane also said uptake of medicines in the UK – which occurs much slower than in other major EU member states – is likely to fall further behind.
Concerns over future of Australian biotech
Australia ranks 5th in the world for biotech innovation on Scientific American’s Worldview, however, industry experts expressed concern about the future of the sector last week.
According to an article in Nature, tax breaks over the past 20 years have allowed Australia to attract a disproportionate level of biotech investment. Likewise Government support for scientific research has fuelled growth.
However, proposed changes to Government programmes and taxation laws have raised concerns. See more details here.
Smashing drugs can illuminate microcrystals say researchers
Scientists have developed a way of finding microcrystals in drug formulations by detecting the light they give off when smashed.
According to a study published in Analytical Chemistry, the team measures triboluminescence – the light given off when the crystals are disrupted – to determine their location in a formulation.
The technique has the potential to help formulators eliminate microcrystals that can reduce solubility in some formulations.
Researcher Steven A. Nowak from AbbVie told C&EN triboluminescence “may be well suited for rapid at-line monitoring during manufacturing and possess sufficient detection limits for the determination of low levels of crystals even in amorphous-solid dispersions with low drug loads.”
Also in the news
Sanofi’s decision to use robotic technologies at its biologics facility in Framingham, Massachusetts will cost nearly 100 people their jobs according to Fiercepharma.
The US is facing a shortage of EpiPens according to a Bloomberg report that says Mylan has warned of intermittent supply problems.
Content management firm Amplexor has published a fascinating blog about how language choice can be used to accelerate drug approvals.